E-Selectin, ICAM-1, and ET-1 Biomarkers Address the Concern of the Challenging Diagnosis of Interstitial Lung Disease in Patients with Autoimmune Diseases.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
07 Aug 2023
Historique:
received: 17 07 2023
revised: 01 08 2023
accepted: 05 08 2023
medline: 14 8 2023
pubmed: 12 8 2023
entrez: 12 8 2023
Statut: epublish

Résumé

Interstitial lung disease (ILD) constitutes the most critical comorbidity in autoimmune diseases (ADs) and its early diagnosis remains a challenge for clinicians. Accordingly, we evaluated whether E-selectin, ICAM-1, and ET-1, key molecules in endothelial damage, could be useful biomarkers for the detection of AD-ILD

Identifiants

pubmed: 37569893
pii: ijms241512518
doi: 10.3390/ijms241512518
pmc: PMC10420063
pii:
doi:

Substances chimiques

Intercellular Adhesion Molecule-1 126547-89-5
E-Selectin 0
Biomarkers 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : ISCIII-ESF
ID : PI21/00042
Organisme : ISCIII-ESF
ID : CPII21/00004

Références

Lung. 2015 Jun;193(3):355-9
pubmed: 25787222
J Cereb Blood Flow Metab. 2016 Jan;36(1):72-94
pubmed: 26058695
Clin Rheumatol. 2018 Jun;37(6):1563-1571
pubmed: 29687288
BMJ. 2016 Feb 24;352:h6819
pubmed: 26912511
Chest. 1995 Jul;108(1):233-9
pubmed: 7541743
Br J Rheumatol. 1997 Dec;36(12):1270-5
pubmed: 9448587
Am J Respir Cell Mol Biol. 2011 Jan;44(1):1-10
pubmed: 20448055
Arthritis Rheum. 2013 Nov;65(11):2737-47
pubmed: 24122180
Int J Mol Sci. 2014 Jun 25;15(7):11324-49
pubmed: 24968272
Eur Respir J. 1998 Jan;11(1):91-8
pubmed: 9543276
Expert Rev Clin Immunol. 2018 Jan;14(1):69-82
pubmed: 29202589
J Clin Med. 2020 May 26;9(6):
pubmed: 32466389
Atherosclerosis. 2012 Oct;224(2):309-17
pubmed: 22673743
Eur Respir J. 2019 Sep 30;54(3):
pubmed: 31371443
J Leukoc Biol. 2020 Sep;108(3):787-799
pubmed: 32182390
Int J Mol Sci. 2023 Jan 26;24(3):
pubmed: 36768729
Acta Med Okayama. 2001 Aug;55(4):205-11
pubmed: 11512562
Semin Arthritis Rheum. 1996 Feb;25(4):215-33
pubmed: 8834012
Am J Respir Crit Care Med. 2020 Mar 15;201(6):650-660
pubmed: 31841044
Am J Respir Cell Mol Biol. 2010 Jan;42(1):16-20
pubmed: 19717811
Arthritis Res Ther. 2022 Feb 9;24(1):39
pubmed: 35139913
Front Mol Biosci. 2022 Dec 19;9:1056121
pubmed: 36601584
Biomedicines. 2022 Apr 05;10(4):
pubmed: 35453601
Respirology. 2016 Feb;21(2):245-58
pubmed: 26212251
Inflammation. 2004 Feb;28(1):1-5
pubmed: 15072224
Ann Rheum Dis. 2008 Aug;67(8):1121-6
pubmed: 18029384
Autoimmun Rev. 2011 May;10(7):416-25
pubmed: 21281743
J Clin Pathol. 1995 Apr;48(4):330-4
pubmed: 7615852
J Immunol. 2010 Aug 15;185(4):2502-15
pubmed: 20624949
Biomedicines. 2021 Jul 20;9(7):
pubmed: 34356910
Am J Respir Cell Mol Biol. 1997 Feb;16(2):187-93
pubmed: 9032126
BioDrugs. 2010 Feb 1;24(1):49-54
pubmed: 20055532
J Clin Med. 2020 Dec 18;9(12):
pubmed: 33353104
Am J Respir Crit Care Med. 2013 Sep 15;188(6):733-48
pubmed: 24032382
J Clin Med. 2019 Nov 21;8(12):
pubmed: 31766446
Lancet Respir Med. 2018 Feb;6(2):138-153
pubmed: 29154106
Ann Rheum Dis. 2021 Feb;80(2):143-150
pubmed: 33037004
Thorax. 2000 Feb;55(2):147-52
pubmed: 10639534
PLoS One. 2014 Feb 06;9(2):e88150
pubmed: 24516598
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595
Rheumatology (Oxford). 2006 Oct;45 Suppl 3:iii8-10
pubmed: 16987839
Arthritis Rheum. 2000 May;43(5):1085-93
pubmed: 10817563
Int J Mol Sci. 2023 Jan 09;24(2):
pubmed: 36674789

Auteurs

Verónica Pulito-Cueto (V)

Immunopathology Group, Marqués de Valdecilla University Hospital-Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.

Sara Remuzgo-Martínez (S)

Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.

Fernanda Genre (F)

Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.

Belén Atienza-Mateo (B)

Immunopathology Group, Marqués de Valdecilla University Hospital-Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.

Víctor M Mora-Cuesta (VM)

Immunopathology Group, Marqués de Valdecilla University Hospital-Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
Department of Pneumology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.

David Iturbe-Fernández (D)

Immunopathology Group, Marqués de Valdecilla University Hospital-Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
Department of Pneumology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.

Leticia Lera-Gómez (L)

Department of Microbiology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.

María Sebastián Mora-Gil (MS)

Immunopathology Group, Marqués de Valdecilla University Hospital-Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.

Virginia Portilla (V)

Immunopathology Group, Marqués de Valdecilla University Hospital-Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.

Alfonso Corrales (A)

Immunopathology Group, Marqués de Valdecilla University Hospital-Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.

Ricardo Blanco (R)

Immunopathology Group, Marqués de Valdecilla University Hospital-Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.

José M Cifrián (JM)

Immunopathology Group, Marqués de Valdecilla University Hospital-Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
Department of Pneumology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
School of Medicine, Universidad de Cantabria, 39011 Santander, Spain.

Miguel A González-Gay (MA)

Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
School of Medicine, Universidad de Cantabria, 39011 Santander, Spain.
Department of Rheumatology, IIS-Fundación Jiménez Díaz, 28040 Madrid, Spain.

Raquel López-Mejías (R)

Immunopathology Group, Marqués de Valdecilla University Hospital-Marqués de Valdecilla Research Institute (IDIVAL), 39011 Santander, Spain.
Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH